AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05286164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 150 mg QD for 8 weeks
Study NCT05587413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal care
Description: periodontal treatment
Study NCT05977465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: treatment
Study NCT04861441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler
Description: Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
Study NCT04861441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Icepacks
Description: Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
Study NCT04748952 — intervention group
Intervention type: DEVICE
Intervention: Densah burs
Description: Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
Study NCT06011096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact and delayed cord clamping
Description: Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
Study NCT06011096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: avoiding skin-to-skin contact and early cord clamping
Description: After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
Study NCT05653973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Study NCT05653973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Description: endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
Study NCT04708483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra DCE-CT scan
Description: DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
Study NCT05120154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online educational materials
Description: The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
Study NCT05120154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational materials
Description: The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
Study NCT05120154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated online webinars
Description: Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
Study NCT04702997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl oral capsule
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
Study NCT04702997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule containing an inert placebo
Study NCT05706636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral mini pulse
Description: 5mg / week oral dexamethasone
Study NCT05706636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical cream
Description: topical fluticasone cream for body lesions and topical tacrolimus for face lesions
Study NCT05706636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: targeted phototherapy
Description: twice weekly targeted excimer light sessions
Study NCT06436495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Wash Shampoo
Description: A standard marketed hair wash shampoo is to be used for the hair wash intervention post baseline evaluations of the scalp.
Study NCT04243122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Description: 2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
Study NCT04243122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: 81mg once per day for 6 months Then treated \& followed up as per standard of care
Study NCT06360705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataMGT
Description: StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
Study NCT06393010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online rehabilitation program
Description: Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
Study NCT02127736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study NCT02127736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02127736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05869877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bundled
Description: An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
Study NCT05914389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Study NCT05914389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
Study NCT05914389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1 Monoclonal Antibody
Description: The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
Study NCT05914389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum
Description: Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
Study NCT05914389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
Study NCT05666479 — intervention group
Intervention type: DEVICE
Intervention: Dexcom G6 Pro Continuous Glucose Monitor (CGM)
Description: A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery.
Study NCT05457114 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)
Description: PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
Study NCT05457114 — intervention group
Intervention type: DEVICE
Intervention: FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)
Description: Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
Study NCT05084599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaraminol 2.7μg/kg/min
Description: After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
Study NCT05084599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metaraminol 2μg/kg/min
Description: After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
Study NCT05397210 — intervention group
Intervention type: DEVICE
Intervention: Infinity-Lock Button System
Description: Infinity-Lock Button System
Study NCT04853498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3720
Description: This is an androgen receptor antagonists.
Study NCT04862832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions.
Study NCT05162898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: 240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
Study NCT05162898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day
Study NCT05162898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
Study NCT05327036 — intervention group
Intervention type: OTHER
Intervention: collect information about all participants
Description: collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
Study NCT05479461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Hypertension Management System
Description: Mobile health technology using physician- directed, semi-automated management of hypertension
Study NCT05479461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The participants will receive usual care
Study NCT06546358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Participants will be randomized to receive either quetiapine or trazodone.
Study NCT06546358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Participants will be randomized to receive either quetiapine or trazodone.
Study NCT04827589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally
Study NCT04827589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study NCT05758987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)
Description: A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
Study NCT05758987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure
Description: A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
Study NCT05124288 — intervention group
Intervention type: OTHER
Intervention: Observations on Relapsed AML Allogeneic Transplanted patients
Description: This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
Study NCT06371469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHeBAC
Description: Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
Study NCT06371469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
Study NCT06239805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.
Study NCT06239805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.
Study NCT06239805 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.
Study NCT06232395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA test
Description: circulating DNA test
Study NCT04696653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Unit Based Safety Program (CUSP)
Description: CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
Study NCT04707365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor samples
Description: for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
Study NCT04766099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childbirth Educational Video
Description: Educational video describing techniques for pushing
Study NCT05412966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-002B
Description: PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
Study NCT05412966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSET-O
Description: reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
Study NCT06300944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
Study NCT06300944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
Study NCT06224036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDB0131
Description: JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.
Study NCT06224036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delamanid
Description: Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.